Investors rewarded Neurocrine Biosciences (NASDAQ: NBIX) on Wednesday for posting a Q1 of fiscal 2020 earnings report that featured encouraging growth in key financials.
The biotech company published the quarterly release after market hours on Tuesday, revealing that it booked revenue of $237.1 million -- 71% higher than the Q1 of fiscal 2019 figure. On the bottom line, under GAAP standards, the company flipped to a net profit of $37.4 million, or $0.39 per share, from a year-ago loss of $102.1 million. Non-GAAP (adjusted) net income nearly tripled, to $79.1 million.
Image source: Getty Images.